Plain English Summary
Background and study aims
Hospital intensive care units (ICUs) can be dangerous places. A year after being discharged, 70% of patients remain 'functionally disabled' due to their hospital stays. One reason for this is muscle wasting experienced in hospital. A treatment called Repetitive Occlusion Stimulus (ROS) is a treatment used to try to prevent muscle wasting. A fabric cuff, similar to that used to measure blood pressure, is placed round one thigh and inflated and deflated repeatedly, causing a restriction and then release of blood flow. This has been shown to effectively reduce muscle wasting in patients who are less ill but it has not been tried in ICU patients before. It is uncomfortable but should not cause any distress. Before ROS is tested on a large number of patients it will be tested on a small sample to check for any problems, either in the use of ROS or in the processes of the study. The aim of this study is to see if it is feasible to design a larger trail with the potential to definitively establish if ROS works.
Who can participate?
Adults aged 18 and older who are admitted to the ICU within the past 36 hours.
What does the study involve?
Participants are randomly allocated to one of two groups. Those in the first group receive standard care. Those in the second group receive the standard care as well as two sessions of Repetitive Occlusive stimulus (ROS) treatment for ten successive days. Each session of ROS lasts 35 minutes and involves placing a pressure cuff, similar to one used to measure the blood pressure, around the patient’s right thigh which is then inflated and deflated over 5 minute intervals, four times to cause restriction and then release of blood flow. The outcome measures which include ultrasound assessment of cross sectional area of rectus femoris muscle, ultrasound assessment of vessels function (resting vessel diameter & blood flow, flow mediated dilation and reactive hyperaemic response) as well as assessment to test the physical function and muscle strength are carried out at baseline (day 1), day 6 &11 of ICU stay, ICU & hospital discharge. After 3 months of hospital discharge, a telephone follow up is carried out.
What are the possible benefits and risks of participating?
Benefits of taking part in the study include close monitoring by the research team such as ultrasound scan for blood clots. Furthermore, there is potential that participant that receives ROS treatment will experience reduced muscle wasting and improved vascular function. For all patients taking part in the study, there is a minor risk (bruising, inflammation or fainting) associated with one episodes of phlebotomy at hospital discharge. To mitigate this risk only suitably qualified and experience staff will be take the blood sample. The pressure used to inflate the cuff for repetitive occlusive stimulus and to measure vascular outcome measure might be uncomfortable. In the unlikely event participant experience unbearable discomfort then pain-killers will be given and the pressures reduced or session stopped immediately. Minor skin irritation/discolouration may occur such as petechias (red spots on the skin caused by burst capillary vessels) and bruising around the pressure cuff. To reduce the risk wider pressure cuff are being used in this study and in addition daily physical examination of leg for any sign of injury will be performed by the research nurse. Also there is a small risk of serious side effects of repetitive occlusive stimulus including severe muscle damage (rhabdomyolysis), a blood clot in the vein (venous thrombus) and/or lungs (pulmonary embolism). These risks are very low. To mitigate these risks, participants are closely monitored. The level of marker for muscle damage (creatinine kinase) are assessed daily, ultrasound scan to assess for blood clot are carried out daily before the first ROS session in treatment group, while on day 1, 6, and 11 in control group.
Where is the study run from?
1. Royal Surrey County Hospital (UK)
2. St Peter’s Hospital (UK)
When is the study starting and how long is it expected to run for?
July 2015 to May 2019
Who is funding the study?
Intensive Care Foundation and NIHR Research for Patient Benefit (UK)
Who is the main contact?
Mr Ben Creagh-Brown
bencb@nhs.net
Trial website
Contact information
Type
Public
Primary contact
Dr Ben Creagh-Brown
ORCID ID
http://orcid.org/0000-0002-4397-1232
Contact details
Consultant and Clinical Lecturer
Royal Surrey County Hospital
Egerton Road
Surrey
Guildford
GU2 7XX
United Kingdom
+44 (0)7974917811
bencb@nhs.net
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
34935
Study information
Scientific title
Preventing muscle wasting in critically ill patients by repetitive occlusive stimulus (ROS): a feasibility study
Acronym
ROSProx
Study hypothesis
The aim of this study is to determine if it is safe, tolerable and feasible to apply treatment called Repetitive Occlusion Stimulus (ROS) as well explore its effectiveness of preventing muscle wasting on a small group of ICU patients and use these results to design a larger trial in the future.
Ethics approval
London Queen Square Research Ethic Committee, 08/09/2017, ref: 17/LO/0934
Study design
Randomised; Interventional; Design type: Treatment, Physical, Rehabilitation
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
Not available in web format, please use the contact details to request a patient information sheet
Condition
Specialty: Critical care, Primary sub-specialty: Critical Care; UKCRC code/ Disease: Generic Health Relevance/ No specific disease
Intervention
Participants recruited to the study are randomised to either treatment group or control group.
Participants in control group receive standard care, while Participants in treatment group receive a treatment called Repetitive Occlusive stimulus (ROS) in addition to standard care. ROS involves placing a pressure cuff, similar to one used to measure the blood pressure, around the patient’s right thigh which is then inflated and deflated repeatedly to cause restriction and then release of blood flow.
Patients in treatment group receive two sessions of ROS from Day 1 to 10 (20 sessions in total) in morning and late afternoon (at least 4 hours apart). Each session of ROS lasts 35 minutes and involves 4 cycles of 5 minutes of inflation and 5 minutes deflation of cuff.
In addition, following assessment are carried to monitor the changes in muscle and blood vessel:
1. On three occasions (days 1, 6 and 11 of ICU stay), ultrasound assessment of muscle and blood vessels is carried out. In addition patients in treatment group receive additional ultrasound scan for blood clots on day 2 to 10 of ICU stay before the first ROS session
2. One urine sample (day 1 of ICU) and four blood samples (day 1, 6 and 11 of ICU, and hospital discharge). Urine is collected from a catheter drainage bag and wherever possible, blood is taken from a cannula (already in place in ICU patients) or via direct venepuncture (at hospital discharge).
3. On four occasions (day 6 and 11 of ICU, and at ICU and hospital discharge) strength of handgrip and other muscle groups using the Medical Research Council (MRC) strength score is assessed
4. On day 1, 6 and 11 of ICU, and at ICU discharge mobility using the ICU Mobility Scale (IMS) are observed, while at hospital discharge in addition physical function assessment ‘Sit to Stand test’ and ‘Get up and Go test’ are carried out
5. At hospital discharge, participant and personal consultee undergo semi-structured interview to assess the acceptability of the trial, and then 3 months after discharge a telephone follow-up are carried out to ask about the health and recovery
Intervention type
Device
Phase
Drug names
Primary outcome measure
The incidence of severe adverse events per participant in the control and treatment group are monitored from the time a personal consultee gives consent for the patient to participate in the study up to 3 months follow-up contact.
Secondary outcome measures
1. Tolerability is measured using pain on visual analog scale (VAS) at each ROS session
2.Feasibility to apply to ICU patients following is assessed using the success rate of screening potential eligible patients, Success rate of obtaining consent and recruiting patients, success rate of delivering ROS session as intended, success rate of performing outcome measure assessment as intended
3. Acceptability for patient, personal consultee and clinical staff is assessed using semi-structured interview at hospital discharge (patients and personal consultee) and at the end of study (clinical staff)
4. Difference in muscle function between control group and treatment group following will be assessed using:
4.1. Cross sectional area of rectus femoris muscle in right leg (control group) and both legs (treatment group) at day 1, 6 and 11 of ICU stay
4.2. Hand grip strength and other muscle group strength using MRC-Sum Score at day 6, 11 of ICU stay (or first day awakening) as well as at ICU and hospital discharge
4.3. Physical function assessment: ICU mobility scale (at day 1, 6, and 11 of ICU stay & ICU and hospital discharge), Sit to Stand & timed up and go (at hospital discharge only)
5. Difference in vascular function between control group and treatment group, reactive hyperaemic response and flow mediated dilatation of superficial femoral artery will be carried out on day 1, 6, 11 of ICU stay
Overall trial start date
19/07/2015
Overall trial end date
05/05/2019
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
1. Age ≥ 18 year, both male & female
2. Admitted to the ICU within the past 36 hours
3. Personal consultee provides declaration of agreement for patient enrolment, retrospective patient consent
4. Invasive mechanical ventilation
5. At least 2 other organ failures as defined by scoring ≥1 points on two of the SOFA score domains
6. Likely to remain on ICU for at least 4 days as classified by attending consultant
Participant type
Patient
Age group
Adult
Gender
Both
Target number of participants
Planned Sample Size: 32; UK Sample Size: 32
Participant exclusion criteria
1. Profound cardiovascular instability – infused vasopressors > = 0.5mcg/kg/min of norepinephrine; or in opinion of senior attending doctor
2. Profound coagulopathy (Prothrombin time> 2.5x normal or platelet count of < 80) or bleeding diathesis
3. Neuromuscular condition – any previous or concurrent neurological condition or muscle disease
4. History of peripheral arterial vascular disease – any previous surgery or interventional procedure for peripheral arterial insufficiency, or any reason to clinically suspect arterial insufficiency of the leg – such as collateral history of claudication or examination findings of absent peripheral pulses
5. Prior amputation of a lower limb
6. Obesity (BMI> 40); due to technical considerations.
7. Unlikely to survive ICU
8. Disseminated malignancy
9. Pregnancy
10. Previous, or current, DVT and PE
11. Positioned prone
12. Contraindication to pharmacological venous thromboembolism prophylaxis
13. Pre-existing significant cognitive impairment
14. Enrolled in a conflicting interventional trial
15. Lack ability to communicate in verbal and written English
Recruitment start date
30/10/2017
Recruitment end date
05/02/2019
Locations
Countries of recruitment
United Kingdom
Trial participating centre
Royal Surrey County Hospital
Egerton Road
Surrey
Guildford
GU2 7XX
United Kingdom
Trial participating centre
St Peter’s Hospital
Guildford Road
Lyne
Chertsey
KT16 0PZ
United Kingdom
Funders
Funder type
Charity
Funder name
Intensive Care Society
Alternative name(s)
Funding Body Type
private sector organisation
Funding Body Subtype
professional associations and societies
Location
United Kingdom
Results and Publications
Publication and dissemination plan
The results of the study will be published in high-impact peer reviewed journal within one year of trial end date. Please use the study contact details above to request a protocol or other study documents.
IPD sharing statement:
The datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication
Intention to publish date
05/05/2020
Participant level data
Other
Basic results (scientific)
Publication list